Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&A Impact with Vivus Deconsolidation

Reuters06-21

Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&A Impact with Vivus Deconsolidation

Petros Pharmaceuticals Inc. has released its unaudited pro forma consolidated balance sheets, shedding light on the financial implications of its recent M&A activities. The statements, dated March 31, 2025, reflect adjustments related to the deconsolidation of subsidiaries and a settlement with Vivus. Notably, the company's common stock saw an increase in issued and outstanding shares to 2,052,762, up from 421,124, as a result of these transactions. Additional paid-in capital rose significantly, reaching approximately $115.99 million, while accumulated deficits were adjusted to $107.99 million. The adjustments also reflect changes in liabilities, with the accounts payable and accrued expenses being notably reduced. These financial statements provide a clearer picture of Petros Pharmaceuticals' financial position following the recent strategic transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Petros Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061230), on June 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2545103843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-21 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545103843","market":"nz","top_or_hot":-1,"title":"Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&A Impact with Vivus Deconsolidation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&amp;A Impact with Vivus Deconsolidation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PTPI\">Petros Pharmaceuticals Inc</a>. has released its unaudited pro forma consolidated balance sheets, shedding light on the financial implications of its recent M&amp;A activities. The statements, dated March 31, 2025, reflect adjustments related to the deconsolidation of subsidiaries and a settlement with Vivus. Notably, the company's common stock saw an increase in issued and outstanding shares to 2,052,762, up from 421,124, as a result of these transactions. Additional paid-in capital rose significantly, reaching approximately $115.99 million, while accumulated deficits were adjusted to $107.99 million. The adjustments also reflect changes in liabilities, with the accounts payable and accrued expenses being notably reduced. These financial statements provide a clearer picture of Petros Pharmaceuticals' financial position following the recent strategic transactions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Petros Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061230), on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&A Impact with Vivus Deconsolidation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPetros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&A Impact with Vivus Deconsolidation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-21 05:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&amp;A Impact with Vivus Deconsolidation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PTPI\">Petros Pharmaceuticals Inc</a>. has released its unaudited pro forma consolidated balance sheets, shedding light on the financial implications of its recent M&amp;A activities. The statements, dated March 31, 2025, reflect adjustments related to the deconsolidation of subsidiaries and a settlement with Vivus. Notably, the company's common stock saw an increase in issued and outstanding shares to 2,052,762, up from 421,124, as a result of these transactions. Additional paid-in capital rose significantly, reaching approximately $115.99 million, while accumulated deficits were adjusted to $107.99 million. The adjustments also reflect changes in liabilities, with the accounts payable and accrued expenses being notably reduced. These financial statements provide a clearer picture of Petros Pharmaceuticals' financial position following the recent strategic transactions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Petros Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061230), on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTPI","symbol_name":"Petros Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLblljgT:1","article_id":"2545103843","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545103843","pubTimestamp":1750454496,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Petros Pharmaceuticals Inc. has released its unaudited pro forma consolidated balance sheets, shedding light on the financial implications of its recent M&A activities. The statements, dated March 31, 2025, reflect adjustments related to the deconsolidation of subsidiaries and a settlement with Vivus. Notably, the company's common stock saw an increase in issued and outstanding shares to 2,052,762, up from 421,124, as a result of these transactions. Additional paid-in capital rose significantly, reaching approximately $115.99 million, while accumulated deficits were adjusted to $107.99 million. The adjustments also reflect changes in liabilities, with the accounts payable and accrued expenses being notably reduced. These financial statements provide a clearer picture of Petros Pharmaceuticals' financial position following the recent strategic transactions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTPI":"Petros Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Petros Pharmaceuticals发布备考财务报表，强调Vivus分拆对并购的影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTPI":0.9},"content_text":"Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&A Impact with Vivus Deconsolidation\n    \n\nPetros Pharmaceuticals Inc. has released its unaudited pro forma consolidated balance sheets, shedding light on the financial implications of its recent M&A activities. The statements, dated March 31, 2025, reflect adjustments related to the deconsolidation of subsidiaries and a settlement with Vivus. Notably, the company's common stock saw an increase in issued and outstanding shares to 2,052,762, up from 421,124, as a result of these transactions. Additional paid-in capital rose significantly, reaching approximately $115.99 million, while accumulated deficits were adjusted to $107.99 million. The adjustments also reflect changes in liabilities, with the accounts payable and accrued expenses being notably reduced. These financial statements provide a clearer picture of Petros Pharmaceuticals' financial position following the recent strategic transactions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Petros Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061230), on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2545103843","isCrawlerRequest":true}